Lixing Yang

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

55h-index51.0kcitations138works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(65), RNA modifications and cancer(24), Epigenetics and DNA Methylation(16), Genomic variations and chromosomal abnormalities(12), Genetic factors in colorectal cancer(11)

Publications94 total

A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Cancer Discovery·2025Open Access
A prognostic signature for lung adenocarcinoma in people who have never smoked
2025Open Access
Examining the Role of Extrachromosomal DNA in Lung Cancer
2025· 3 citedOpen Access
Abstract LB263: A transcriptomic signature predicts mortality risk and immune checkpoint inhibitor response beyond molecular and morphological features in lung adenocarcinoma from never smokers
Cancer Research·2025
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition
2025· 5 citedOpen Access
Supplementary Data 1 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Supplementary Table S3 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Supplementary Table S2 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Data from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Supplementary Table S1 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer
Nature Cancer·2024· 9 citedOpen Access
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Clinical Cancer Research·2024· 16 citedOpen Access
HYENA detects oncogenes activated by distal enhancers in cancer
Nucleic Acids Research·2024· 3 citedOpen Access
Abstract B006: Data-driven discoveries of molecular mechanism and therapeutic vulnerabilities of CDK12 mutant tumors
Molecular Cancer Therapeutics·2024
Mapping recurrent mosaic copy number variation in human neurons
Nature Communications·2024· 12 citedOpen Access
Abstract LB226: Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition
Cancer Research·2024
Abstract LB228: Evolutionary trajectories of lung cancer in never smokers
Cancer Research·2024
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Cell Reports·2024· 13 citedOpen Access
Somatic structural variation signatures in pediatric brain tumors
Cell Reports·2023· 9 citedOpen Access
SFyNCS detects oncogenic fusions involving non-coding sequences in cancer
Nucleic Acids Research·2023· 8 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Peter J. Park(30), Lynda Chin(12), Semin Lee(12), Kadir C. Akdemir(12), Dmitry A. Gordenin(12), Jake June-Koo Lee(12), Raju Kucherlapati(11), Rameen Beroukhim(11), Isidro Cortés‐Ciriano(11), Ruibin Xi(11), Rehan Akbani(10), Xiaojia Ren(10), Marcin Imieliński(9), Leszek J. Klimczak(9), Cheng‐Zhong Zhang(9), David A. Wheeler(9), Alexei Protopopov(9), Gordon B. Mills(8), Angela Hadjipanayis(8), Yilong Li(8)